LyophilisedPT141
PT-141 (Bremelanotide)
10mg≥99.5% Purity
Pharmaceutical-grade PT-141 (Bremelanotide), FDA-approved for hypoactive sexual desire disorder.
Request a Quote
Pricing available for qualified medical professionals, clinics, and distributors.
Enquire NowDownload MonographView FAQMechanism of Action
PT-141 (Bremelanotide) is a cyclic melanocortin peptide that activates MC3R and MC4R in the hypothalamus. Unlike PDE5 inhibitors (sildenafil), it acts centrally on the CNS to enhance sexual desire and arousal pathways. It is the only FDA-approved treatment that targets the brain rather than peripheral vasculature for sexual dysfunction.
Clinical Benefits
- Central MC3R/MC4R activation in hypothalamus
- FDA-approved for hypoactive sexual desire disorder
- Mechanism distinct from PDE5 inhibitors
- Effective in both male and female patients
Specifications
TypeCyclic melanocortin peptide
TargetMC3R/MC4R (hypothalamus)
Purity≥99.5% (HPLC verified)
Storage & Handling
- Store at -20°C
- Reconstituted: 2–8°C
- Protect from light
For professional medical use only. Not for retail sale to the general public. Pricing available on request for qualified medical institutions and distributors.